Health Care & Life Sciences » Pharmaceuticals | Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
12,032.00
13,018.00
15,752.00
22,997.00
30,704.00
Depreciation, Depletion & Amortization
705.00
738.00
1,038.00
864.00
649.00
Other Funds
2,739.00
1,533.00
-
-
-
Funds from Operations
13,353.00
14,522.00
4,146.00
21,335.00
29,282.00
Changes in Working Capital
16,675.00
14,256.00
13,957.00
1,768.00
556.00
Net Operating Cash Flow
3,322.00
266.00
18,103.00
19,567.00
28,726.00
Capital Expenditures
156.00
1,529.00
551.00
279.00
315.00
Sale of Fixed Assets & Businesses
10.00
-
-
-
-
Purchase/Sale of Investments
11,326.00
1,715.00
10,745.00
47,563.00
24,609.00
Net Investing Cash Flow
11,472.00
3,244.00
10,194.00
47,842.00
24,294.00
Issuance/Reduction of Debt, Net
1,701.00
-
-
-
6,893.00
Net Financing Cash Flow
4,391.00
41,124.00
278.00
23,964.00
7,070.00
Net Change in Cash
22,212.00
34,076.00
13,375.00
41,556.00
3,391.00
Free Cash Flow
3,478.00
1,263.00
18,654.00
19,846.00
29,041.00
Change in Capital Stock
49.00
42,657.00
278.00
23,964.00
177.00
Exchange Rate Effect
3,027.00
4,070.00
5,744.00
1,889.00
753.00

About Xenon Pharmaceuticals

View Profile
Address
3650 Gilmore Way
Burnaby British Columbia V5G 4W8
Canada
Employees -
Website http://www.xenon-pharma.com
Updated 07/08/2019
Xenon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in discovering and developing a pipeline of differentiated therapeutics. It has built a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.